Treace Medical Concepts, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $212.7M | $209.4M | $187.1M | $141.8M | $94.4M | $57.4M | $39.4M |
| Cost of Revenue | $42.9M | $41.1M | $35.2M | $25.5M | $16.9M | $12.5M | $7.6M |
| Gross Profit | $169.8M | $168.3M | $151.9M | $116.3M | $77.5M | $44.9M | $31.8M |
| Gross Margin | 79.8% | 80.4% | 81.2% | 82.0% | 82.1% | 78.3% | 80.6% |
| Operating Expenses | |||||||
| Research & Development | $20.3M | $20.6M | $15.4M | $13.6M | $10.2M | $5.8M | $5.1M |
| SG&A Expense | $62.7M | $55.7M | $47.0M | $33.0M | $18.4M | $6.5M | $4.5M |
| Operating Income | $-54.2M | $-55.7M | $-51.4M | $-34.8M | $-16.5M | $855.0K | $-3.5M |
| Operating Margin | -25.5% | -26.6% | -27.5% | -24.6% | -17.5% | 1.5% | -9.0% |
| Interest Expense | $5.3M | $5.3M | $5.2M | $4.4M | $4.1M | $2.8M | $841.0K |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-59.0M | $-55.7M | $-49.5M | $-42.8M | $-20.6M | $-3.7M | $-4.3M |
| Net Margin | -27.7% | -26.6% | -26.5% | -30.2% | -21.8% | -6.4% | -10.8% |
| EPS (Basic) | $-0.93 | $-0.90 | $-0.81 | $-0.77 | $-0.43 | $-0.12 | $-0.13 |
| EPS (Diluted) | $-0.93 | $-0.90 | $-0.81 | $-0.77 | $-0.43 | $-0.12 | $-0.13 |
| Shares Outstanding (Basic) | 63.3M | 62.1M | 60.9M | 55.3M | 48.4M | 37.1M | — |
| Shares Outstanding (Diluted) | 63.3M | 62.1M | 60.9M | 55.3M | 48.4M | 37.1M | — |
| Dividends Per Share | — | — | — | — | — | — | — |